Validation of the use of B-type natriuretic peptide point-of-care test platform in preliminary recognition of cardioembolic stroke patients in the ED

2015 ◽  
Vol 33 (4) ◽  
pp. 521-526 ◽  
Author(s):  
Zhixin Wu ◽  
Mingming Zhao ◽  
Mingfeng He ◽  
Hongke Zeng ◽  
Feng Tan ◽  
...  
2017 ◽  
Vol 1 (2) ◽  
pp. 165-176 ◽  
Author(s):  
Prima Dewi Sinawang ◽  
Dorin Harpaz ◽  
Luka Fajs ◽  
Raymond Chee Seong Seet ◽  
Alfred Iing Yoong Tok ◽  
...  

Abstract Stroke is the second top leading cause of death globally. It is caused by an abrupt interruption of blood flow to the brain. In that course, brain natriuretic peptide (BNP) and its derivative N-terminal pro b-type natriuretic peptide (NT-proBNP), neurohormones produced mainly by the heart ventricles in response to excessive stretching of cardiomyocytes (heart muscle cells), are proven to be good biomarkers for heart failure diagnosis. Moreover, there is growing clinical interest of the use of NT-proBNP for stroke diagnosis and prognosis because it is significantly associated with cardioembolic stroke and secondary stroke reoccurrence, with sensitivity >90% and specificity >80%. However, in diagnostic settings, there is still a need to address the encountered analytical problems, particularly assay specificity and set up. In this study, a novel approach for NT-proBNP detection is demonstrated using an electrochemical immunoassay method. A label-free impedimetry immunosensor for stroke biomarker was developed using modified disposable screen-printed gold electrodes (SPGE) hosting specific anti-NT-proBNP capture antibody. The performance of our immunosensor was studied in the presence of NT-proBNP in both buffered and mock (porcine) plasma samples. A linear relation between the relative total resistance (ΔRtot) responses and the NT-proBNP concentrations in buffer was observed in a range from 0.1 to 5 ng mL-1 with a correlation coefficient (R2) of 0.94656. Overall, the biosensor has demonstrated the capability to quantitate NT-proBNP and differentiate such concentrations in a low concentration range, especially among 0, 0.1, 0.5, 1, and 3 ng mL-1 in plasma samples within 25 min. This range is valuable not only for classifying cardioembolic stroke (higher or equal to 0.5 ng mL-1), but also predicting the risk of secondary stroke reoccurrence (higher than 0.255 ng mL-1). Our biosensor has the potential to be used as an easy-to-use point-of-care test that is both accurate and affordable.


2014 ◽  
Vol 32 (3) ◽  
pp. 337-344 ◽  
Author(s):  
Rene Ritter ◽  
Jörg Hennenlotter ◽  
Ursula Kühs ◽  
Udo Hofmann ◽  
Stefan Aufderklamm ◽  
...  

Author(s):  
Dong Jin Shin ◽  
Mitra Lewis ◽  
Yu-Hsiang Hsieh ◽  
Noha Atef Rahmoun ◽  
Charlotte A. Gaydos ◽  
...  

2000 ◽  
Vol 2 ◽  
pp. 90-90
Author(s):  
Jen Koon ◽  
Padma Krishnaswamy ◽  
Radmilia Casengra ◽  
Nancy Gardetto ◽  
Anthony DeMaria ◽  
...  

Biosensors ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 107 ◽  
Author(s):  
Dorin Harpaz ◽  
Raymond C. S. Seet ◽  
Robert S. Marks ◽  
Alfred I. Y. Tok

Stroke is a widespread condition that causes 7 million deaths globally. Survivors suffer from a range of disabilities that affect their everyday life. It is a complex condition and there is a need to monitor the different signals that are associated with it. Stroke patients need to be rapidly diagnosed in the emergency department in order to allow the admission of the time-limited treatment of tissue plasminogen activator (tPA). Stroke diagnostics show the use of sophisticated technologies; however, they still contain limitations. The hidden information and technological advancements behind the utilization of biomarkers for stroke triaging are significant. Stroke biomarkers can revolutionize the way stroke patients are diagnosed, monitored, and how they recover. Different biomarkers indicate different cascades and exhibit unique expression patterns which are connected to certain pathologies in the human body. Over the past decades, B-type natriuretic peptide (BNP) and its derivative N-terminal fragment (NT-proBNP) have been increasingly investigated and highlighted as significant cardiovascular biomarkers. This work reviews the recent studies that have reported on the usefulness of BNP and NT-proBNP for stroke triaging. Their classification association is also presented, with increased mortality in stroke, correlation with cardioembolic stroke, and an indication of a second stroke recurrence. Moreover, recent scientific efforts conducted for the technological advancement of a bedside point-of-care (POC) device for BNP and NT-proBNP measurements are discussed. The conclusions presented in this review may hopefully assist in the major efforts that are currently being conducted in order to improve the care of stroke patients.


Sign in / Sign up

Export Citation Format

Share Document